Core Insights - MannKind has undergone significant changes in the past month, indicating a transformation in its business strategy and operations [5]. Company Overview - MannKind has been in operation for 34 years, originally focusing on inhalation therapeutics, particularly in diabetes [5]. - The company has diversified its focus away from diabetes over the last 7 to 8 years, aiming to apply its inhalation technology in areas that can create the most impact for shareholders, patients, and employees [5].